Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07246213
Recruiting Observational

CAYA Cancer Retrospective Cohort Study

NCT07246213 · tracked via the Priya Life Science Egypt tracker
Sponsor
Resonance, Inc
Phase
Observational
Started
2025-06-04
Last updated
2026-09-29

Condition(s) studied

Acute Lymphoblastic LeukemiaLymphoblastic LymphomaYoung Adult CancerAdolescent CancerChildhood CancersAcute Lymphoblastic Leukemia (ALL)Lymphoblastic Lymphoma (LBL)

Investigational drug(s) / intervention(s)

Retrospective Medical Record Review

Retrospective Medical Record Review: This study involves retrospective review of medical records of pediatric, adolescent, and young adult cancer patients (ages 0-21 years) treated at participating oncology centers in Guatemala, Honduras, El Salvador, Armenia, and Tanzania. No experimental drug, device, or behavioral intervention is being administered. Data abstraction will be performed to assess treatment failure, therapy-related toxicities, and clinical outcomes.

Study summary

Despite advances in cancer treatment, significant disparities in outcomes persist between high-income countries (HICs) and low-and middle-income countries (LMICs). Around 80% of children with cancer live in LMICs, where they face challenges such as delayed diagnosis, misdiagnosis, comorbidities, distance to treatment, financial barriers, and limited access to risk-adapted therapies.

Acute lymphoblastic leukemia(ALL)/lymphoblastic lymphoma(LBL), for example, is one of the greatest success stories in pediatric oncology, however, such improvements are not evenly distributed worldwide, and the outcomes for leukemia patients are poorer in LMICs compared to HICs, primarily due to reduced access to quality healthcare.

This study aims to assess cancer treatment outcomes in LMICs, focusing on acute lymphoblastic leukemia/lymphoblastic lymphoma. The findings will inform future studies to implement evidence-based interventions that improve care quality and reduce treatment failures through targeted strategies.

Eligibility

Sex
ALL
Min age
0 Years
Max age
21 Years
Healthy volunteers
No
Inclusion Criteria: Subjects must meet all the following criteria to be included in this registry: 1. Participants must be willing and able to provide informed consent prior to enrollment in the registry. 1. For minors or individuals unable to provide informed consent, assent must be obtained along with consent from a legal guardian. 2. Note: Exemption applies to this criterion when waiver of informed consent/assent is granted by Institutional Review Board(IRB)/Independent Ethics Committee(IEC)/Competent Authorities(CAs). 2. A confirmed diagnosis of any type of cancer within the 15 years prior to the site's activation date. 3. Age 0 to 21 years at the time of diagnosis. 4. Received substantial anti-cancer treatment at the participating center, including but not limited to: 1. Chemotherapy 2. Surgery 3. Radiation therapy 4. Immunotherapy 5. Medical records are available and accessible for review Exclusion Criteria: * Subjects meeting any of the following criteria will be excluded from this registry: 1. Patients who only visited the participating center for: 1. Consultation without subsequent primary anti-cancer treatment at the participating center 2. Pathology, radiology, or other diagnostic evaluations without treatment

Primary outcome measure(s)

  • To estimate the incidence of treatment failure, in patients with any type of cancer diagnosis. — 3 years from date of cancer diagnosis (retrospective follow-up via medical records; patients without an event will be censored at last contact within 3 years)
  • To estimate the incidence of Grade 3, 4, and 5 therapy-related toxicities in patients diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma. — 3 years from date of cancer diagnosis (retrospective follow-up via medical records; patients without an event will be censored at last contact within 3 years)

Trial sites (7)

FacilityCityRegionStatus
Yeolyan Center for Cancer and Blood Disorders Yerevan Armenia Recruiting
The Children's Cancer Hospital Egypt 57357 Cairo Egypt Not Yet Recruiting
Fundación Ayúdame a Vivir El Salvador El Salvador Recruiting
Unidad Nacional de Oncología Pediátrica (UNOP) Guatemala City Guatemala Recruiting
Hospital Mario Catarino Rivas San Pedro Sula Cortés Department Recruiting
Hospital Escuela Tegucigalpa Distrito Central Recruiting
Kilimanjaro Christian Medical Center Moshi Tanzania Not Yet Recruiting

More Resonance, Inc. trials in Egypt

CAYA Cancer Prospective Cohort Study Recruiting

Other trials for the same condition

Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia Recruiting
CAYA Cancer Prospective Cohort Study Recruiting
Hepatoprotective Measures for Children at High Risk of NAFLD Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07246213 on ClinicalTrials.gov ↗ ← All trials in Egypt